Norges Bank
ZYNE

Norges Bank’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Norges Bank’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,000
Closed -$72K – 2270
2015
Q3 		$72K Buy
+5,000
New +$123K ﹤0.01% 2259

Other funds holding ZYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFA
Nationwide Fund Advisors Columbus, Ohio $2.42B AUM 17.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's ZYNE Position: Q4 2015 in Review

Norges Bank sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2015, closing a stake of 5,000 shares — an estimated $72K sold.

Norges Bank first reported a position in ZYNE in Q3 2015 and held it in 1 quarter. The position peaked at $72K in Q3 2015. 31 funds tracked by Wall St. Rank hold ZYNE as of Q4 2015.

  • Norges Bank reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2015 after selling out during the quarter.
  • Norges Bank sold 5,000 Zynerba Pharmaceuticals, Inc shares in Q4 2015, an estimated $72K.
  • Norges Bank first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 1 quarter.
  • Norges Bank's Zynerba Pharmaceuticals, Inc position peaked at $72K in Q3 2015.
  • 31 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2015.

Based on Norges Bank's 13F filing for Q4 2015, filed 10 Feb 2016.